Authors
Bon-Kwon Koo, Jeehoon Kang, Kyung Woo Park, Tae-Min Rhee, Han-Mo Yang, Ki-Bum Won, Seung-Woon Rha, Jang-Whan Bae, Nam Ho Lee, Seung-Ho Hur, Junghan Yoon, Tae-Ho Park, Bum Soo Kim, Sang Wook Lim, Yoon Haeng Cho, Dong Woon Jeon, Sang-Hyun Kim, Jung-Kyu Han, Eun-Seok Shin, Hyo-Soo Kim, Heesun Lee, Kyoo-Rok Han, Keon-Woong Moon, Seok Kyu Oh, Ung Kim, Moo-Yong Rhee, Doo-Il Kim, Song-Yi Kim, Sung-Yun Lee, Seung Uk Lee, Sang-Wook Kim, Seok Yeon Kim, Hui-Kyung Jeon, Kwang Soo Cha, Sang-Ho Jo, Jae Kean Ryu, Il-Woo Suh, Hyun-Hee Choi, Seoung-Il Woo, In-Ho Chae, Won-Yong Shin, Dae-Kyeong Kim, Ju Hyeon Oh, Myung Ho Jeong, Yong Hoon Kim
Publication date
2021/6/26
Journal
The Lancet
Volume
397
Issue
10293
Pages
2487-2496
Publisher
Elsevier
Description
Background
Optimal antiplatelet monotherapy during the chronic maintenance period in patients who undergo coronary stenting is unknown. We aimed to compare head to head the efficacy and safety of aspirin and clopidogrel monotherapy in this population.
Methods
We did an investigator-initiated, prospective, randomised, open-label, multicentre trial at 37 study sites in South Korea. We enrolled patients aged at least 20 years who maintained dual antiplatelet therapy without clinical events for 6–18 months after percutaneous coronary intervention with drug-eluting stents (DES). We excluded patients with any ischaemic and major bleeding complications. Patients were randomly assigned (1:1) to receive a monotherapy agent of clopidogrel 75 mg once daily or aspirin 100 mg once daily for 24 months. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due …
Total citations
Scholar articles
BK Koo, J Kang, KW Park, TM Rhee, HM Yang… - The Lancet, 2021